AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06579339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: xylitol chewing gum
Description: Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
Study NCT06579339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: xylitol chewing gum
Description: Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
Study NCT05080946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery.
Study NCT05080946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery.
Study NCT05806229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid transverse process to pleura block (MTP)
Description: After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura.After negative aspiration to avoid intravascular injection levobupivacaine 0.5% and dexamethazone 4mg total volume 21ml will be injected
Study NCT05806229 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Mid transverse process to pleura Sham block
Description: After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura. with 2ml normal saline subcutaneously will be injected
Study NCT05109091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH434 dose level 1
Description: ATH434 taken BID
Study NCT05109091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH434 dose level 2
Description: ATH434 taken BID
Study NCT05109091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken BID
Study NCT05275192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videoscope-assisted periodontal regeneration minimally invasive surgery
Description: Use of a videoscope to improve visualization of periodontal defect during minimally invasive surgery
Study NCT05275192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal regeneration minimally invasive surgery
Description: Conventional periodontal regeneration minimally invasive surgery without use of a videoscope
Study NCT05275192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided tissue regeneration surgery
Description: Conventional guided tissue regeneration surgery for periodontal regeneration without use of a videoscope
Study NCT05732909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-β-hydroxybutyrate/D 1,3 butanediol monoester
Description: Ketone monoester
Study NCT06079463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercise
Description: Step 1: Take a comfortable position (sitting or lying down) and wear comfortable, non-tightening clothes.~Step 2: Try to relax with eyes closed, without focusing on thoughts, by focusing on your own body muscles.~Step 3: Right and left, respectively, hands, arms (triceps muscle), chest, abdomen, hips, legs (thigh muscles), feet and toes, neck, shoulder (scapula muscles) and muscle groups on the face (around the eyes, chin) and eyebrow muscles) by concentrating on contracting and relaxing these muscles.~Step 4: Focusing on the muscle groups of the whole body, contracting and relaxing.~Step 5: Opening the eyes slowly, trying to feel the feeling of comfort in the body (Turkish Psychologists Association Progressive Relaxation Exercises).
Study NCT06235801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given by PO
Study NCT06235801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Given by PO
Study NCT06052241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: shampoos and scalp serums
Description: shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
Study NCT06198465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil
Description: adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；
Study NCT05988996 — intervention group
Intervention type: BEHAVIORAL
Intervention: Participant guided peer support gathering
Description: This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.
Study NCT01512901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Microsphere (DE-102） Low Dose
Study NCT01512901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Microsphere (DE-102） High Dose
Study NCT01512901 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT03584737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: rapid in vitro diagnostic test
Description: IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Included in quadruple eradication medication.
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Included in quadruple eradication medication.
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline tid
Description: Included in quadruple eradication medication.
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline qid
Description: Included in quadruple eradication medication.
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Included in quadruple eradication medication.
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Included in quadruple eradication medication.
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Pectin
Description: Included in quadruple eradication medication.
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin
Description: Included in quadruple eradication medication.
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20mg
Description: Included in quadruple eradication medication.
Study NCT05431075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: Included in quadruple eradication medication.
Study NCT04131608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBC ,Serum ferritin ,HBA1C
Description: Diabetic patients will be applied to CBC, HBA1C and serum ferritin
Study NCT05560048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice protein RP-80N
Description: rice protein RP-80NY were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
Study NCT05560048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
Study NCT06240325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPP
Description: SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
Study NCT06240325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Psychoeducation
Description: Using the pamphlet also used in SPP, SPE will present sleep hygiene practices commonly included in sleep education programs and endorsed by national health organizations.
Study NCT06545760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC) support for > 2 days
Description: Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home
Study NCT06545760 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Kangaroo mother care (KMC) support for < 2 days
Description: Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home
Study NCT05142592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG7236
Description: The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
Study NCT04496219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture therapy
Study NCT04496219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture Therapy
Description: Undergo acupuncture therapy
Study NCT04496219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Solution
Description: Given by intravesical injection
Study NCT04496219 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG Solution
Description: Given by intravesical injection
Study NCT04496219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care symptom management
Study NCT04496219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care symptom management
Study NCT04920201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over-ground walking without GEMS-H
Description: Over-ground walking without GEMS-H (30 min per session, at least 3 times per weeks, total 10 sessions)
Study NCT04920201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-ground walking with GEMS-H with resist mode
Description: Over-ground walking with GEMS-H with resist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
Study NCT04496219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04496219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04496219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04496219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06219317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is provided in a 10 ml glass vial
Study NCT06219317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: standard saline solution
Study NCT03584737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: bacterial culture
Description: Quantitative bacterial culture assay with isolate identification by MALDI-TOF.
Study NCT03584737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR assay
Description: Semiquantitative real-time PCR assay
Study NCT05642026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients in this group will receive CINB (continuous local intercostal infusion of 0.2% Ropivacaine). A single catheter will be placed for short segment involvement and two catheters will be placed in series for longer segments of involvement. If necessary and as part of standard of care, CINB treatment will continue after patient discharge. The administration of CINB therapy will continue in the same manner as inpatient therapy.
Study NCT05642026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non steroidal anti-inflammatory drug and opioids
Description: Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
Study NCT05642026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non steroidal anti-inflammatory drug and opioids
Description: Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
Study NCT05055791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1903
Description: SYHX1903 tablets, orally, qd
Study NCT06484192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500 Mg
Description: participants will receive Naproxen (500 mg) to take for 7 days after surgery as needed
Study NCT06484192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: participants will receive Ketorolac (15 mg) immediately after surgery
Study NCT06484192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: participants will receive OxyCODONE (5 mg) to take for 7 days after surgery as needed
Study NCT06484192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaxalone 800 MG
Description: participants will receive Metaxalone (800 MG) to take for 7 days after surgery as needed
Study NCT05923359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: Apple Watch
Study NCT04920201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stair ascent with GEMS-H with assist mode
Description: Stair ascent with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
Study NCT04920201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incline walking with GEMS-H with assist mode
Description: Incline walking with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
Study NCT05862350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy inhalation with lavender essential oil
Description: patients in the experimental group will receive aromatherapy inhalation by 4 drops of 50% lavender essential oil，which is diluted with coconut essential oil， on the cotton chip in the diffuser clip for 8 hours each night during sleep
Study NCT05862350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aromatherapy inhalation with coconut essential oil.
Description: patients in the experimental group will receive aromatherapy inhalation by 4 drops of 100% coconut essential oil on the cotton chip in the diffuser clip for 8 hours each night during sleep
Study NCT05221151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
Study NCT06104033 — intervention group
Intervention type: DEVICE
Intervention: drug-coated balloon
Description: For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.
Study NCT06104033 — intervention group
Intervention type: DEVICE
Intervention: drug-eluting stent
Description: When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.
Study NCT06174714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)
Description: 4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.
Study NCT05808049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MXP22 (Probiotic and antioxidant capsule)
Description: Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
Study NCT05808049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Microcrystalline Cellulose)
Description: Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
Study NCT05748912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic bronchoscopy for removal of mucus plugs
Description: Research participants that meet the study inclusion criteria will undergo a research bronchoscopy to remove airway mucus plugs from 1 lung for the first 5 participants, and, if single lung mucus removal is well tolerated, on both lungs for the next 5 participants.
Study NCT05221151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
Study NCT05221151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: before spinal anaesthesia
Study NCT05240482 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ST36 acupuncture
Description: ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed).
Study NCT05240482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ST36 acupuncture
Description: ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed).
Study NCT06383585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oZTEo
Description: An FDA approved MRI pulse sequence, oZTEo, will be added to a standard of care MRI examination. The oZTEo pulse sequence will be anonymized and sent to GE Healthcare for the application of a deep learning algorithm, 3D DL.